TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

Read full text Summarise with VIRAT
Authors: Sarah Spoeck, Nadine Kinz, Irene Rigato, Katharina Hoppe, Julia Heppke, Paul Y. Petermann, Johannes G. Weiss, Miriam Erlacher, Michaël Schubert, Joel S. Riley, Andreas Villunger, Francesca Finotello
+1 more Verena Labi
Cited by: 0
References: 102

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The DNA demethylase ten-eleven translocation enzyme 2 (TET2) is frequently inactivated in hematologic malignancies, yet how its loss shapes oncogene-driven transformation remains unclear. Using a mouse model in which MYC is overexpressed in the B cell lineage, driving aggressive B cell lymphoma, we show that Tet2 loss increases lymphoma penetrance and biases disease toward an IgM+ immunophenotype. Established lymphomas are broadly similar across genotypes, suggesting that Tet2 loss exerts much of its effects before lymphoma onset. Accordingly, Tet2 loss expands a premalignant IgM+ B cell subset with reduced apoptotic sensitivity and an increased frequency of BCL2+BIMhi cells. Consistently, Tet2 deficient IgM+ B cells persist better in in vitro cultures, show increased clonogenic survival, and exhibit clonal skewing. These findings support a model in which Tet2 loss heightens MYC-driven lymphoma penetrance by promoting the survival and selection of premalignant B cells under apoptotic stress.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Epigenetics and DNA Methylation Acute Myeloid Leukemia Research

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
21 March 2026
Language
EN
Document type
Preprint